文献速递间质性肺疾病

血清YKL-40是肺泡蛋白沉积症的可靠生物标志物

Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.
PubMed 文献 · Respirology · 2017-05-31

本研究纳入34例自身免疫性肺泡蛋白沉积症(PAP)患者和50例健康对照,检测血清和BALF中YKL-40水平及CHI3L1基因多态性。PAP患者血清和BALF的YKL-40均显著高于对照,血清YKL-40与DLCO相关,基线300 ng/mL可预测疾病进展(HR 7.875,P=0.001)。

要点

  • PAP患者血清和BALF中YKL-40水平显著高于健康对照
  • 血清YKL-40与DLCO相关,可预测疾病进展
  • 基线血清YKL-40≥300 ng/mL提示进展风险升高(HR 7.875)

核心结论

  • YKL-40在PAP患者血清和BALF中升高,可能有助于预测PAP的结局。

研究设计与样本

  • 研究纳入34例自身免疫性PAP患者和50例健康对照。
  • 采用ELISA检测血清和BALF中YKL-40水平,PCR和焦磷酸测序检测CHI3L1-329和-131基因多态性。

主要发现

  • 基线血清YKL-40在PAP患者为286 ± 27 ng/mL,高于对照的42 ± 4 ng/mL(P < 0.0001)。
  • 基线BALF中YKL-40在PAP患者为323 ± 36 ng/mL,高于对照的3 ± 1 ng/mL(P < 0.0001)。
  • 血清YKL-40与基线DLCO相关(P = 0.002),并与随访DLCO相关(P < 0.0001)。
  • 疾病进展患者基线血清YKL-40高于稳定或改善患者(P < 0.0001)。
  • 基线血清YKL-40 cut-off 300 ng/mL预测疾病进展的HR为7.875(P = 0.001)。

关键数值与推荐

  • 基线血清YKL-40 cut-off 300 ng/mL预测PAP疾病进展(HR 7.875,P = 0.001)。
  • G等位基因与血清和BALF中YKL-40水平升高相关。

临床怎么用

  • 可考虑检测血清YKL-40辅助评估PAP疾病进展风险。
  • 基线血清YKL-40≥300 ng/mL提示需密切随访疾病进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by alveolar filling. YKL-40, a chitinase-like protein produced by macrophages and epithelial cells, is increased in patients with interstitial lung diseases. We aimed to evaluate the role of YKL-40 as a biomarker for PAP. METHODS: A total of 34 patients with autoimmune PAP and 50 healthy controls were studied. YKL-40 was measured by ELISA in serum and bronchoalveolar lavage fluid (BALF). Chitinase coding gene polymorphisms (CHI3L1-329 and -131) were detected by PCR and pyrosequencing. Correlations between serum YKL-40 levels and disease outcome were analysed. RESULTS: Baseline serum and BALF levels of YKL-40 were higher in PAP patients than in controls (286 ± 27 ng/mL vs 42 ± 4 ng/mL, P < 0.0001; 323 ± 36 ng/mL vs 3 ± 1 ng/mL, P < 0.0001, respectively). Serum YKL-40 levels correlated with diffusing capacity of the lung for carbon monoxide (DLCO ) at baseline (P = 0.002) and over time (P < 0.0001). Patients with disease progression had higher baseline serum YKL-40 levels than those who remained stable or improved (P < 0.0001). A baseline cut-off level of 300 ng/mL was predictive of disease progression (HR (hazard ratio): 7.875, P = 0.001). The presence of the G allele was associated with higher serum and BALF levels of YKL-40. CONCLUSION: YKL-40 is elevated in serum and BALF of PAP patients, and may be of clinical utility to predict outcome in PAP.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Bonella F, Long X, He X, et al. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis. Respirology. 2017. PMID: 28569052. doi:10.1111/resp.13082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。